(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
latest_posts
- 1
Uranus's small moons are dark, red, and water-poor - 2Key takeaways from Sen. Bill Cassidy's interview on 'Face the Nation' with Margaret Brennan
- 3Atorvastatin recall may affect hundreds of thousands of patients – and reflects FDA’s troubles inspecting medicines manufactured overseas
- 4NASA chief Jared Isaacman says Texas may get a moonship, not space shuttle Discovery
- 5Dick Van Dyke shares his secrets to longevity as he turns 100
- Damaged launch pad: How long before Russia can send astronauts to the ISS again?
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
- The Force of Organic product: 10 Assortments That Improve Your Wellbeing
- The Main 15 Applications for Efficiency and Association
- The most effective method to Stay away from Normal Traps While Recruiting a Material Organization
- The Way to Recuperation: Defeating Dependence
- 6 Shades Brands For Seniors
- CDC vaccine panel delays vote to stop recommending hepatitis B shot at birth
- Figure out How to Remain Persuaded During Your Internet based Degree Program
